NewAmsterdam Pharma Co N.V.
10-K
February 18, 2026
Key Highlights
- Lead drug candidate, obicetrapib, is advancing through pivotal Phase 3 clinical ...
- Company maintains a strong cash position of $350 million, providing a projected ...
- Critical Phase 3 trial results (BROADWAY and BROOKLYN) are expected in mid-2026 ...
Read Analysis
🤖 AI Generated